Genzyme Corporate Genetics Home Search Contact Us Genzyme Websites
Test Menu Health Care Professionals Patients Managed Care Organizations About Genzyme Genetics
Genzyme Genetics

Quick Links:
 Go
 
Search
 Go
Locations and Licenses
Research
Events
News
Careers

Genzyme Genetics Events

Oncology/Pathology

Oncology/Pathology Events Recorded Webcast - KRAS: The Newly Recognized Central Biomarker for EGFR-Directed Therapy

KRAS activating mutations play a key role in neoplastic progression and are particularly prevalent in colorectal, pancreatic, and lung cancers. Recent studies have shown a significant correlation between KRAS mutations and non-response to targeted therapeutic agents for both NSCLC and colorectal adenocarcinoma.


The webcast on KRAS mutation analysis addresses the following questions:
-Why are KRAS mutations important?
-Where do they occur?
-What are the differences between KRAS mutations in NSCLC and CRC?
-What does it mean for treatment selection?
-What does it mean to the patient?


Presenter: Bruce C. Horten, M.D., Medical Director, Genzyme Genetics-New York

Register to view the recorded webcast.


Chemotherapy Foundation Symposium XXVI
New York, NY
November 5-7, 2008


CSP - California Society of Pathologists
Los Angeles, CA
December 3-6, 2008


ASH – American Society of Hematology
San Francisco, CA
December 6-8, 2008


  Contact Information

Genzyme Genetics
Tel: (800) 357-5744
Fax: (508) 389-5577

Reproductive/Genetics Client Services
Tel: (800) 848-4436

Shipping information

Oncology/Pathology Client Services
Tel: (800) 447-5816

Shipping information

Terms and Conditions of Use | Privacy Policy | © 2002-2008 Genzyme Corporation. All rights reserved.